- Home
- KLRS vs KG Comparison
KLRS vs KG Comparison
Compare KLRS & KG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KLRS | KG |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.1M | 87.3M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | KLRS | KG |
|---|---|---|
| Price | $3.94 | $7.71 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 53.3K | 11.5K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.70 | ★ 1819.15 |
| EPS | ★ N/A | N/A |
| Revenue | $165,000.00 | ★ $34,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 785.08 |
| 52 Week Low | $3.03 | $7.07 |
| 52 Week High | $11.88 | $29.13 |
Technical Indicators
Market Signals| Indicator | KLRS | KG |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 40.19 |
| Support Level | $3.92 | N/A |
| Resistance Level | $4.37 | $8.17 |
| Average True Range (ATR) | 0.25 | 0.49 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 22.00 | 27.04 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About KG Kestrel Group Ltd.
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.